Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Human Cold Inducible RNA Binding Protein (CIRBP), Active Protein

Product Sizes
50 ug
£991.00
RPU54980-50UG
100 ug
£1209.00
RPU54980-100UG
1 mg
£5014.00
RPU54980-1MG
About this Product
SKU:
RPU54980
Additional Names:
A18HNRNP|CIRP|Glycine-Rich RNA Binding Protein
Application:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Extra Details:
Human Cold Inducible RNA Binding Protein (CIRBP), Active Protein is a purified Prokaryotic Protein.
Formulation:
Freeze-dried powder
Immunogen:
Cold Inducible RNA Binding Protein (CIRBP)
Molecular Weight:
25kDa
Physical State:
freeze-dried
Purity:
>95%
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles.
Supplier:
Biomatik
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
CIRBP (Cold-inducible RNA-binding protein) is considered to play a protective role in the genotoxic stress response by stabilizing transcripts of genes involved in cell survival and act as a translational activator. Besides, ATXN1 (Ataxin-1) has been proven as an interactor of CIRBP. Thus a binding ELISA assay was conducted to detect the interaction of recombinant human CIRBP and recombinant human ATXN1. Briefly, CIRBP were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to ATXN1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-CIRBP mAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of CIRBP and ATXN1 was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 2. SDS-PAGE